7月27日（路透社）——迈心诺公司（Masimo Corp）宣布，其儿科患者状态指数（Pediatric Patient State Index）已获得美国食品药品监督管理局（FDA）的510(k)上市前许可。这一创新产品是首款、也是唯一一款专门针对儿童大脑独特生理特征而设计的镇静评分工具。
7月27日（路透社）——迈心诺公司（Masimo Corp）宣布，其儿科患者状态指数（Pediatric Patient State Index）已获得美国食品药品监督管理局（FDA）的510(k)上市前许可。这一创新产品是首款、也是唯一一款专门针对儿童大脑独特生理特征而设计的镇静评分工具。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.